MLE 4901

Drug Profile

MLE 4901

Alternative Names: AZD 4901; MLE4901

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Small molecules
  • Mechanism of Action Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hot flashes; Polycystic ovary syndrome

Most Recent Events

  • 02 Nov 2016 Interim pharmacodynamics data from a preclinical study in Polycystic ovary syndrome released by Millendo Therapeutics
  • 16 Aug 2016 Millendo Therapeutics initiates enrolment in a phase II trial for Polycystic ovary syndrome in USA
  • 29 Jul 2016 Millendo Therapeutics plans a phase II trial for Polycystic ovary syndrome in United Kingdom (UKCtr35928)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top